Ornament Leads $18m Financing Round of Swiss Blood Diagnostic Startup Spiden
The ambitious startup began with an idea that soon the human body and modern medical technology will become one. Continuously monitoring the body’s condition in real time will become possible, thanks to the introduction of a next-generation blood diagnostic implantable device. Once in the realm of science fiction, Spiden is working hard on making this a near reality.
Spiden’s financing round came to a total of $18 million. Ornament Health AG leads the round, contributing almost half of the investment.
Snezhana Gurina, Executive Director of Ornament Health AG: “We have been studying issues related to human longevity for a long time, and we are constantly working in this direction. Innovative Spiden technology fits perfectly with the principles of preventive medicine, which are the basis of Ornament’s ideology. We believe that by investing in revolutionary medical developments it is possible to increase people’s life expectancy, as well as significantly improve its quality.”
Unique development
Spiden’s biomaterial analysis technology differs from classic laboratory analysis methods in that it does not destroy the sample during processing. The accuracy of the data is not affected by reagents, preservatives, or any other manipulation. All measurements take place inside the body under ideal conditions.
Spectral methods allow qualitative and quantitative analysis simultaneously. Each chemical element has a strictly defined resonant frequency. As a result, atoms of the element can either emit or absorb light at their specific frequency. This technology allows us to cover a wide range of different wavelengths and study all spectral processes (absorption, Raman scattering, phosphorescence, fluorescence, etc.), which allows us to generate signals from the blood for a wide range of biomarkers.
Data analysis and biomarker library: Modern artificial intelligence methods consulting a library of biomarkers allows for real-time quantification in the body.
Microtechnology (miniaturization): A unique approach to the design of the optomechanical unit, sensors, and microchip design that allows for implantation. The microchip can also be used to visualize research results across tests such as endoscopies.
Leo Grünstein, the founder and CEO of Spiden: “Our mission is to develop medical technologies that will improve the lives of millions of people by continuously monitoring health indicators and therefore supporting timely and personalized diagnostics.”
Mission and Implementation
Spiden is currently increasing the number of biomarkers and drugs it is able to monitor, raising its relevance for both chronically ill patients as well as healthy individuals such as professional athletes. Grünstein is confident that by the end of the decade, continuous real-time monitoring of biomarkers and drugs will be widely available via miniaturized implants. In comparison with one-off blood tests, real-time monitoring enables observation of trends and correlations between biomarkers, drugs, supplements, and our health, unlocking the basis for preventative medicine and extended longevity.
